Table 2.
Demographic, laboratory, and clinical variables of HAP.
| Characteristics | Value |
|---|---|
| Age >70 years | 409 (35.3%) |
| Gender: male | 723 (62.4%) |
| Smoke | 248 (21.4%) |
| Diabetes mellitus | 230 (19.9%) |
| COPD | 55 (4.7%) |
| Antibiotics therapy in the preceding 90 days | 566 (48.9%) |
| Stomach tube intubation | 307 (26.5%) |
| Central venous catheterization | 197 (17.0%) |
| Use of PPI | 745 (64.3%) |
| ICU admission | 30 (2.6%) |
| ALB <30 g/L | 124 (10.7%) |
| WBC, ×109/L | 10.44 ± 5.72 |
| Lymphocyte count <0.8 ∗ 109/L | 327 (28.2%) |
| NLR | 9.08 ± 9.06 |
| BUN/ALB | 0.21 ± 0.17 |
| MDR pathogens | 193 (16.7%) |
| Related mortality | 150 (13.0%) |
HAP: hospital-acquired pneumonia; COPD: chronic obstructive pulmonary disease; use of PPI: use of proton-pump inhibitor; ICU admission: intensive care unit admission; ALB: albumin; WBC: white blood cell; NLR: neutrophil-to-lymphocyte count ratio; BUN/ALB: blood urea nitrogen/blood albumin; MDR: multidrug resistant.